Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:08:46 2024-05-17 EDT			5-day change	1st Jan Change
0.279 ^SEK	0.00%		-12.54%	+7.31%

04-30	Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	CI
04-25	Annexin Pharmaceuticals AB Announces Updates on Last Patient is Treated with the Investigational New Drug ANXV in the Phase 2A Study	CI

Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals

April 30, 2024 at 03:22 am

Annexin Pharmaceuticals AB (publ) announced that the final patient has been treated in the phase II study with ANXV for the eye disease retinal vein occlusion. A total of 15 patients have been treated, and the results so far show a favorable safety profile and promising efficacy signals. The company is expected to present top-line data during the summer of 2024.

Latest news about Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	04-30	CI
Annexin Pharmaceuticals AB Announces Updates on Last Patient is Treated with the Investigational New Drug ANXV in the Phase 2A Study	04-25	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2024	04-12	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-09	CI
Annexin Pharmaceuticals AB Provides Update on RVO Study Confirms Promising Signals of Effect	02-08	CI
Annexin Pharmaceuticals AB Announces Additional Patent Protection in the US	11-14	CI
Annexin Pharmaceuticals AB Announces First Patient Treated in the Second Dose Group in RVO Study	23-10-25	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-18	CI
Annexin Pharmaceuticals AB Announces Success in the Cancer Initiative	23-09-29	CI
Annexin Pharmaceuticals AB Announces Promising Signals of Effect in RVO- Study	23-08-11	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-17	CI
Annexin Pharmaceuticals AB Auditor Raises 'Going Concern' Doubt	23-04-18	CI
Annexin Reports First Imaging- Study Results in Retinal Vein Occlusion	23-04-18	CI
Annexin Pharmaceuticals Names New Finance Chief	23-03-21	MT
Annexin Pharmaceuticals AB Appoints Susanne Andersson as CFO	23-03-21	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-07	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-07	CI
Annexin Pharmaceuticals AB Appoints Dr. Alain Thibault as Therapeutic Area Head of Oncology	23-01-18	CI
Annexin Pharmaceuticals Doses First Patient in Phase 2 Trial of Retinal Vein Occlusion Treatment	22-11-08	MT
Annexin Pharmaceuticals AB Announces First Patient Dosed in Annexin's Phase 2 Study in Retinal Vein Occlusion	22-11-08	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-23	CI
Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-30	CI
Annexin Pharmaceuticals Wins US FDA Nod for Mid-Stage Trial of Retinal Vein Occlusion Drug Candidate	22-04-05	MT

Chart Annexin Pharmaceuticals AB

Duration

Period

More charts

Company Profile

Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâs main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Sector

Biotechnology & Medical Research

Calendar

2024-08-19 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Chiffre d''affaires - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ANNEXIN PHARMACEUTICALS AB	+7.31%	9.03M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs